Table 4:
Treatment contrasts for all secondary outcomes
| Treatment Outcomes (Months 1-12) |
Follow-up Outcomes (Month 18) |
||||||
|---|---|---|---|---|---|---|---|
| Outcome | Contrast | Estimate | 95% CI | P-value | Estimate | 95% CI | P-value |
| Square-root PDHDa | TAU - TMC | -- | -- | -- | −0.32 | (−1.46, 0.82) | 0.576 |
| TAU - ACHESS | -- | -- | -- | 0.16 | (−0.86, 1.18) | 0.764 | |
| TAU – TMC+ACH | -- | -- | -- | 0.37 | (−0.55, 1.29) | 0.434 | |
| TMC - ACHESS | -- | -- | -- | 0.48 | (−0.66, 1.62) | 0.405 | |
| TMC – TMC+ACH | -- | -- | -- | 0.69 | (−0.33, 1.71) | 0.187 | |
| ACHESS – TMC+ACH | -- | -- | -- | 0.21 | (−0.73, 1.15) | 0.663 | |
| Any Drinkingb | TAU - TMC | 1.10 | (0.26, 1.94) | 0.010 | −0.17 | (−1.09, 0.75) | 0.715 |
| TAU - ACHESS | 0.64 | (−0.14, 1.42) | 0.108 | −0.48 | (−1.36, 0.40) | 0.291 | |
| TAU – TMC+ACH | 0.89 | (0.13, 1.65) | 0.025 | −0.48 | (−1.34, 0.38) | 0.275 | |
| TMC - ACHESS | −0.46 | (−1.30, 0.38) | 0.276 | −0.31 | (−1.25, 0.63) | 0.520 | |
| TMC – TMC+ACH | −0.22 | (−1.04, 0.60) | 0.607 | −0.31 | (−1.21, 0.59) | 0.500 | |
| ACHESS – TMC+ACH | 0.25 | (−0.51, 1.01) | 0.526 | −0.00 | (−0.88, 0.88) | 0.996 | |
| Drug Usec | TAU - TMC | −0.03 | (−0.87, 0.81) | 0.938 | 0.23 | (−0.75, 1.21) | 0.653 |
| TAU - ACHESS | 0.20 | (−0.58, 0.98) | 0.610 | −0.44 | (−1.36, 0.48) | 0.347 | |
| TAU – TMC+ACH | 0.38 | (−0.40, 1.16) | 0.340 | −0.48 | (−1.34, 0.38) | 0.281 | |
| TMC - ACHESS | 0.24 | (−0.58, 1.06) | 0.573 | −0.67 | (−1.69, 0.35) | 0.200 | |
| TMC – TMC+ACH | 0.42 | (−0.40, 1.24) | 0.321 | −0.70 | (−1.66, 0.26) | 0.152 | |
| ACHESS – TMC+ACH | 0.18 | (−0.60, 0.96) | 0.651 | −0.03 | (−0.95, 0.89) | 0.945 | |
| SIP-R Totald | TAU - TMC | 1.82 | (−2.16, 5.80) | 0.370 | −1.37 | (−7.49, 4.75) | 0.661 |
| TAU - ACHESS | 1.59 | (−2.13, 5.31) | 0.403 | 1.24 | (−4.66, 7.14) | 0.681 | |
| TAU – TMC+ACH | 1.35 | (−2.37, 5.07) | 0.478 | 0.42 | (−5.17, 6.01) | 0.882 | |
| TMC - ACHESS | −0.23 | (−4.21, 3.75) | 0.910 | 2.61 | (−4.23, 9.45) | 0.454 | |
| TMC – TMC+ACH | −0.47 | (−4.41, 3.47) | 0.816 | 1.79 | (−4.56, 8.14) | 0.581 | |
| ACHESS – TMC+ACH | −0.24 | (−3.96, 3.48) | 0.900 | −0.82 | (−6.94, 5.30) | 0.793 | |
| SF12 MHe | TAU - TMC | 4.31 | (−1.84, 10.46) | 0.170 | 8.62 | (−1.30, 18.54) | 0.088 |
| TAU - ACHESS | 2.95 | (−2.75, 8.65) | 0.313 | 3.84 | (−4.90, 12.58) | 0.389 | |
| TAU – TMC+ACH | 3.58 | (−2.10, 9.26) | 0.217 | 5.95 | (−3.03, 14.93) | 0.194 | |
| TMC - ACHESS | −1.36 | (−7.48, 4.76) | 0.663 | −4.78 | (−14.72, 5.16) | 0.347 | |
| TMC – TMC+ACH | −0.73 | (−6.83, 5.37) | 0.816 | −2.67 | (−12.63, 7.29) | 0.598 | |
| ACHESS – TMC+ACH | 0.64 | (−5.08, 6.36) | 0.827 | 2.10 | (−7.13, 11.33) | 0.656 | |
| SF12 PHe | TAU - TMC | 2.93 | (−5.95, 11.81) | 0.518 | −4.04 | (−16.68, 8.60) | 0.531 |
| TAU - ACHESS | −0.61 | (−8.82, 7.60) | 0.885 | 1.62 | (−10.10, 13.34) | 0.786 | |
| TAU – TMC+ACH | 5.45 | (−2.74, 13.64) | 0.193 | −1.72 | (−12.52, 9.08) | 0.755 | |
| TMC - ACHESS | −3.54 | (−12.40, 5.32) | 0.434 | 5.67 | (−7.72, 19.06) | 0.407 | |
| TMC – TMC+ACH | 2.51 | (−6.25, 11.27) | 0.574 | 2.32 | (−9.93, 14.57) | 0.710 | |
| ACHESS – TMC+ACH | 6.05 | (−2.14, 14.24) | 0.148 | −3.35 | (−15.09, 8.39) | 0.576 | |
Analyses controlled for recruitment site, gender, any drug use at baseline, and the baseline version of the outcome variable (except PDHD was used for Any Drinking). The two binary outcomes, Any Drinking and Any Drug Use, have log-odds-ratios (LOR) in the Estimates column.
Percent days heavy drinking (≥5 drinks/day for men, ≥4 drinks/day for women). Primary outcome months 1-12; secondary outcome month 18
Percent of participants with any alcohol use
Percent of participants with any indication of use of cocaine, amphetamines, opiates, barbiturates, benzodiazepines, or THC from urine toxicology or self-report (1=positive, 0= negative)
Short Inventory of Problems. Higher scores indicate more negative consequences for drinking
Short Form Survey. Higher scores indicate better mental health (MH) or physical health (PH)